

Bristol-Myers Squibb Company

September 8, 2006

Dear Customer,

Following a review of the commercial demand for the pharmaceutical products on the attached list, Bristol-Myers Squibb has decided to discontinue the manufacture and sale of DESYREL[®], trazodone, (a list of the discontinued presentations is attached) in the U.S. and its territories effective immediately.

Patients may continue to use these products until their physician has prescribed an alternate therapy. Please maintain current inventories to satisfy those requirements.

The Bristol-Myers Squibb Return Goods Policy will continue to apply to all products noted on the attachment.


If you have any questions related to this announcement, please don't hesitate to call your Bristol-Myers Squibb Account Director or me at 609-897-2412.

Thank you for your continued support of Bristol-Myers Squibb products.

Sincerely,

A handwritten signature in black ink, appearing to read "Vincent J. Bilinsky". The signature is fluid and cursive, with a vertical line to its left.

Vincent J. Bilinsky
Vice President, Trade Sales/Operations



Bristol-Myers Squibb Company

Product	NDC Number	Description
DESYREL [®] trazodone HCl tablets, USP	0087-0775-41	50 mg tablet, bottle of 100
DESYREL [®] trazodone HCl tablets, USP	0087-0775-43	50 mg tablet, bottle of 1,000
DESYREL [®] trazodone HCl tablets, USP	0087-0776-41	100 mg tablet, bottle of 100
DESYREL [®] trazodone HCl tablets, USP	0087-0776-43	100 mg tablet, bottle of 1,000
DESYREL [®] DIVIDOSE [®] trazodone HCl tablets, USP	0087-0778-41	150 mg tablet, bottle of 100
DESYREL [®] DIVIDOSE [®] trazodone HCl tablets, USP	0087-0778-44	150 mg tablet, bottle of 500
DESYREL [®] DIVIDOSE [®] trazodone HCl tablets, USP	0087-0796-41	300 mg tablet, bottle of 100